The Crohn's & Colitis Foundation of America (CCFA) will be hosting IBD Clinical Trials Workshop: Principles and Practice on January 13-14, 2017 at the Renaissance Marriott Hotel in Nashville, Tennessee. The workshop is a multi-disciplinary program with broad participation; bringing together the inflammatory bowel disease (IBD) clinical trials community from academia, the pharmaceutical and clinical device industries, government agencies, medical centers, and clinical research organizations.
"The clinical trials workshop will convene professionals from different disciplines in the IBD field, providing an opportunity to discuss how the future of clinical trials can be shaped from their unique perspectives," Alandra Weaver, MPH, CCFA's Director, Quality of Care and Clinical Research Programs. "The goal is to work toward creating groundbreaking studies for greater advancements in the treatment of inflammatory bowel diseases."
Topics will include effective clinical trials management and recruitment strategies used to maximize trial success, designing clinical protocols that reflect patient considerations, shifting views on clinical trial end points, and thoughts on the future of IBD clinical research. The first day's schedule will include information sessions: State of the Art: IBD Therapy and Clinical Trials in IBD; Understanding the Drug Development Process; and Ethical Issues, Safety, Data Integrity, and Trial Design. During the second day participants will attend breakout sessions on how to plan and start a clinical trial; organizational strategies, measuring outcomes, and understanding the challenges, pitfalls, and future of IBD trials.
The faculty for this workshop includes key opinion leaders and experts that will share their experience and input into current and future IBD clinical investigation.
Visit www.ibdctworkshop.com for more information and to register.
The IBD Clinical Trials Workshop: Principles and Practice is supported in part by sponsorships from AbbVie and Eli Lilly and Company, and a grant from Gilead Sciences, Inc.
